Compare AIRE & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | BFRI |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | 94 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.2M |
| IPO Year | 2023 | N/A |
| Metric | AIRE | BFRI |
|---|---|---|
| Price | $2.07 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.30 | ★ $2.75 |
| AVG Volume (30 Days) | 69.0K | ★ 209.6K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | $14.36 |
| Revenue Next Year | $83.72 | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $0.57 |
| 52 Week High | $3.98 | $1.19 |
| Indicator | AIRE | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 50.13 |
| Support Level | $1.89 | $0.74 |
| Resistance Level | $2.40 | $1.06 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 38.27 | 38.74 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.